FDA Approves New First-Line TNBC Regimen - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

  • By

  • Kathryn Wighton

  • June 26, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New First-Line TNBC Regimen

  • by Kathryn Wighton

  • June 26, 2026

Related Content

Medical debt linked to higher late-stage cancer rates

Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study